Pineal Tumors

Model Introduction

The pineoblastoma orthotopic xenograft model provides a clinically relevant preclinical platform for evaluating novel therapeutic strategies for this rare and aggressive pediatric brain tumor. Pineoblastoma primarily affects children, with infants having little chance of cure, and limited effective treatment options available. This model enables assessment of targeted therapies alone or in combination with conventional chemotherapeutics.

Model Information

Model Construction

Orthotopic xenograft models were established by implanting 2 × 10⁵ cells/μL luciferase-expressing pineoblastoma cells into the right cerebral hemisphere of 10-12 week old athymic female mice. Tumor growth was monitored by bioluminescence imaging.

Fig. 1 Workflow of Pituitary adenoma mouse model establishment and treatment regimen. (Source: Alfa Cytology)

In Vivo Efficacy Evaluation

This study employed established orthotopic pineoblastoma xenograft models to evaluate the therapeutic efficacy of drug A, the pan-ERBB inhibitor, alone and in combination with conventional chemotherapy.

• Drug A Monotherapy: Drug A alone failed to induce apoptosis (cleaved caspase-3) in either 452.Luc2 or 453.Luc2 xenografts.
• Combination with chemotherapy: In both pineoblastoma models, chemotherapy treatment appeared to increase apoptosis, but this effect was not enhanced by co-administration of drug A. No change in proliferation was observed in any treatment group.

Fig. 2 Drug A fails to enhance chemotherapy response in pineoblastoma xenograft models. Data are presented as mean ± SEM. (Source: Alfa Cytology)